China’s NMPA Holds Meeting on AI in Drug Regulation

The signal here is procedural rather than technological: NMPA is framing AI as a chain-wide regulatory object spanning R&D through clinical use, which implies future rulemaking will touch sponsors, manufacturers and distributors alike, not just software vendors. Pledging to 'stabilize expectations' and move review services earlier suggests the agency wants predictability as a competitive draw for innovative pipelines. The open question is how a 'special plan' translates into concrete review standards and timelines, and whether earlier-stage engagement becomes a formal pathway or stays informal.